MammaPrint + BluePrint

A new standard when it comes to Breast Cancer Treatment

MammaPrint + BluePrint in combination enables the Oncologist to make the best treatment decision for the breast cancer patient.

Have Peace of Mind in Your Treatment

A test to predict risk of breast cancer recurrence

MammaPrint is a genomic test to predict risk of breast cancer recurrence. It analyses the 70 most important genes associated with breast cancer recurrence and classifies patients into "Low Risk" and "High Risk" of developing metastases within the first 10 years after diagnosis.

BluePrint is a test to predict tumor behavior in breast cancer. It analyses the activity of 80 genes to stratify a tumor into three subtypes:
- LUMINAL-TYPE: Are responsive to hormonal (anti-estrogen) therapy.
- HER2-TYPE: Grow rapidly and may recur, can be treated with anti HER2 therapies.
- BASAL-TYPE: Grow rapidly, do not respond to hormone therapy or anti-HER2 targeted therapy

Molecular subtyping matters

Not all breast cancers respond the same to neoadjuvant therapy.
BluePrint identified and reclassified 13% of clinically Luminal type patients (ER+ by IHC) as genomically Basal-type. In response to neoadjuvant chemotherapy, these ER+, Basal-type tumors had a Pathological Complete Response (pCR) rate of 34.5%, similar to pCR rate (37.6%) of triple negative; much greater pCR than Luminal-B (5.6%) or Luminal-A (2.3%) patients.

Evidence matters for node positive patients

Not all lymph node positive breast cancers are the same. Only mammaprint is recommended by all major guidelines for node positive patients.


In MINDACT, clinical prospective randomised MammaPrint trial of 6,693 early stage patients including 700 LN+ patients; 48% of clinically high risk patients were genomically "Low Risk" by MammaPrint + BluePrint and spared chemotherapy.
Furthermore 96% of 1-3 LN+ MammaPrint low risk patients were treated with only adjuvant endocrine therapy.
MammaPrint + BluePrint results in combination enables the Oncologist to make the best treatment decision for the breast cancer patient.

MammaPrint + BluePrint tests are run at the same time on the same tumor tissue sample (FFPE) to provide results in ten days. This is the only FDA cleared test that is designed for women of all ages who:
• Are newly diagnosed with invasive early-stage breast cancer (Stage I or II)
• Have a tumor size up to 5 cm
• Are either lymph node-negative or have 1-3 positive lymph nodes

Your care should be as unique and individualised as you are!

I am an educationist, a wife, a mother and a breast cancer survivor. I thought everyone who gets breast cancer diagnosis gets the same treatment but I learned that is not the case. After surgery at Shifa International Hospital, I met with my radiation oncologist and he recommended a genomic test MammaPrint+BluePrint to help determine the expected course of my disease and treatment options. It is a binary test with definitive answers, either you are “Low Risk” or “High Risk” for recurrence. I decided to get my tumor tissue block tested and received the results in two weeks.

I believe every patient should understand their treatment and how it impacts their quality of life. I am so thankful I had the MammaPrint+BluePrint test and it came back that I was "Low Risk" and did not need chemotherapy.

Allah is merciful. The test results changed my life physically and emotionally. My treatment plan after surgery was adjuvant endocrine therapy.

I feel cured.

Mrs Durrani - 2019

Over 75,000 women worldwide have chosen MammaPrint to help evaluate their risk of breast cancer recurrence. BluePrint test helps predict tumor behavior and better predict a patient's prognosis.

Recommended by expert medical guidelines

MammaPrint is included in numerous clinical practice guidelines developed by world-recognized cancer care organizations. Clinical guidelines are evidence-based recommendations for healthcare professionals involved in the management of patients.

Guidelines aim to improve the quality of care and services based on the most up to date peer-reviewed evidence. For example, MammaPrint is the only test of its kind endorsed by the American Society of Clinical Oncology for lymph node-positive patients.

Also included in the National Comprehensive Cancer Network® (NCCN®)

70-Gene Assay (MammaPrint) has a Category 1 recommendation from the National Comprehensive Cancer Network® (NCCN®). Category 1 is based upon high-level evidence; there is uniform NCCN consensus that intervention is appropriate. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © 2019 National Comprehensive Cancer Network, Inc 2019. All rights reserved. To view the most recent and complete version of the guidelines, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

70-gene Assay (MammaPrint) is the only genomic assay with FDA clearance and Level 1 evidence by the American Society of Clinical Oncology (ASCO).